Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel

被引：30

作者：

Ishitobi M. ^{[1
]}

Shin E. ^{[1
]}

Kikkawa N. ^{[1
]}

机构：

[1] Department of Surgery, Osaka National Hospital, Chuo-ku, Osaka 540-0006

来源：

International Journal of Clinical Oncology | 2001年 / 6卷 / 1期

关键词：

Metastatic breast cancer; Paclitaxel; Resistance to anthracycline and docetaxel;

D O I：

10.1007/PL00012081

中图分类号：

学科分类号：

摘要：

We report the case of a 38-year-old woman who underwent surgery for stage III-b breast cancer, and whose liver metastasis failed to respond to both docetaxel (administered at 30-40mg/m2 every 2 weeks as a 1-h intravenous infusion) and epirubicin (administered as a 40-60mg/m2 bolus hepatic arterial infusion). For subsequent treatment, this patient was managed with weekly paclitaxel. The regimen showed some usefulness for the treatment of the liver metastasis, as indicated by an improvement in performance status and tolerable toxicity. This case demonstrates that weekly paclitaxel may be well tolerated and useful for patients with extensive metastatic breast cancer that was resistant to treatment. Our findings also suggest that paclitaxel could be used as a salvage therapy in patients with anthracycline- and docetaxel-resistant breast cancer.

引用

页码：55 / 58

页数：3

共 9 条

[1]

Adachi I., Taguchi T., The clinical utility of docetaxel in adriamycin-resistant breast cancer, Breast Cancer, 4, pp. 273-279, (1997)

[2]

Itou Y., Horikoshi N., Watanabe R., Et al., A phase II study of paclitaxel in patients with recurrent and/or advanced breast cancer - 3-hour infusion, Shinyaku to Rinsho (New Med), 46, pp. 476-486, (1997)

[3]

D'Andrea G.M., Seidman A.D., Docetaxel and paclitaxel in breast cancer therapy: Present status and future prospects, Semin Oncol, 24, SUPPL. 13, pp. 1327-1344, (1997)

[4]

Verweij J., Clavel M., Chevalier B., Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind, Ann Oncol, 5, pp. 495-505, (1994)

[5]

Bissey M.C., Guenard D., Gueritte-Voegelein F., Et al., Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue, Cancer Res, 51, pp. 4845-4852, (1991)

[6]

Valero V., Jones S.E., Von Hoff D.D., Et al., A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer, J Clin Oncol, 16, pp. 3362-3368, (1998)

[7]

Seidman A.D., Hochhauser D., Gollub M., Et al., Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer, J Clin Oncol, 14, pp. 1877-1884, (1996)

[8]

Seidman A.D., One-hour paclitaxel via weekly infusion. Dose-density With enhanced therapeutic index, Oncology, 12, pp. 19-22, (1998)

[9]

Seidman A.D., Hudis C.A., McCaffrey J., Et al., Dose-dense therapy With paclitaxel via weekly 1-hour infusion: Preliminary experience in the treatment of metastatic breast cancer, Semin Oncol, 24, pp. 72-76, (1997)

← 1 →